Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
1060
Trial Sponsor
Clinical Trial Start Date
July 2, 2021
0Primary Completion Date
December 10, 2021
0Study Completion Date
December 10, 2021
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
SYNB16180
SYNB19340
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase 1, Dose-escalation, Placebo- and Active-Controlled Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1934 and the Effect of Concomitant Proton Pump Inhibitor Administration in Healthy Volunteers0
Last Updated
May 18, 2022
0Allocation Type
Randomized0
Intervention Model
Crossover Assignment0
Masking Type
Triple0
Masked Party
Participant0
Investigator0
Care Provider0
Study summary
This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV). Eligible subjects receive investigational product (IP) and undergo safety monitoring, evaluations, and subsequent follow-up after IP administration.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
